Back to Market返回行情

CMND Clearmind Medicine Inc.

USHealthcare

$6.60+0.00%ClosedMarket Cap: $1.2M

As of 2026-10-08

Why CMND matters now

Clearmind Medicine Inc. (CMND) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.60 with +0.00% on the session and $1.2M in market capitalization; recent performance reads 1-month +30.08% and YTD -83.04%.

The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-3.9M, and EPS of $-3.32. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -229.3%.

The latest indexable market news headline is "NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations" from TheNewswire.

Additional event context on this page matters because recent insider activity includes HRT FINANCIAL LP filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

—

PEG

—

P/B

0.08

P/S

0.00

EV/EBITDA

1.12

DCF Value

$1.01

FCF Yield

-229.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-138.2%

ROA

-54.4%

ROIC

-69.7%

Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0.00	$-3.9M	$-3.32
Q4 2025	$0.00	$-687.8K	$-0.48
FY 2025	$0.00	$-3.9M	$-3.03
Q3 2025	$0.00	$-1.3M	$-0.98

Trading Activity

Insider Trades

HRT FINANCIAL LP10 percent owner

Sell2026-06-18

HRT FINANCIAL LP10 percent owner

Sell2026-06-17

HRT FINANCIAL LP10 percent owner

Sell2026-06-16

HRT FINANCIAL LP10 percent owner

Sell2026-06-12

HRT FINANCIAL LP10 percent owner

Sell2026-06-12

Related Stocks

Can-Fite BioPharma Ltd.

Calidi Biotherapeutics, Inc.

CNS Pharmaceuticals, Inc.

Jaguar Health, Inc.

Latest News

NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine CombinationsTheNewswire · 2026-09-23

Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine CombinationsGlobeNewsWire · 2026-09-23

Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property PortfolioTheNewswire · 2026-09-17

Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.GlobeNewsWire · 2026-09-17

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical TrialGlobeNewsWire · 2026-09-11

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

CA

Exchange

—

Beta

-1.24

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.